GetTopicDetailResponse(id=bd8611e70716, topicName=奧來魯單抗, introduction=, content=胰腺導(dǎo)管腺癌 度伐利尤單抗 奧來魯單抗, image=null, comments=0, allHits=720, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Sat Aug 10 14:52:34 CST 2024, time=2024-08-10, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=487781, tagList=[TagDto(tagId=487781, tagName=奧來魯單抗)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2219391, encodeId=579a2219391fc, content=<a href='/topic/show?id=fd55839636c' target=_blank style='color:#2F92EE;'>#胰腺導(dǎo)管腺癌#</a> <a href='/topic/show?id=7b2910612398' target=_blank style='color:#2F92EE;'>#度伐利尤單抗#</a> <a href='/topic/show?id=bd8611e70716' target=_blank style='color:#2F92EE;'>#奧來魯單抗#</a>, objectTitle=CLIN CANCER RES | 奧來魯單抗與度伐利尤單抗聯(lián)合化療治療胰腺導(dǎo)管腺癌患者的 1b/2 期隨機(jī)臨床試驗(yàn), objectType=article, longId=838420, objectId=68a0838420cf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240810/1723256986849_6145188.jpg, objectUrl=/article/show_article.do?id=68a0838420cf, replyNumber=0, likeNumber=126, createdTime=2024-08-10, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=68a0838420cf, moduleTitle=CLIN CANCER RES | 奧來魯單抗與度伐利尤單抗聯(lián)合化療治療胰腺導(dǎo)管腺癌患者的 1b/2 期隨機(jī)臨床試驗(yàn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=68a0838420cf)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-08-10發(fā)表于上海
